<DOC>
	<DOCNO>NCT00068068</DOCNO>
	<brief_summary>The purpose study determine whether Litx platform safe effective treatment liver metastasis arise colorectal cancer . Litx next-generation photodynamic therapy platform drug , talaporfin sodium ( LS11 ) , activate light light-emitting diode ( LED ) -based light infusion device , insert directly tumor skin prior treatment .</brief_summary>
	<brief_title>Photodynamic Therapy With Talaporfin Sodium ( LS11 ) Treating Patients With Refractory Colorectal Liver Metastases</brief_title>
	<detailed_description>Patients provide Informed Consent satisfy Eligibility Criteria undergo CT ultrasound guide percutaneous placement single , two , three , four light infusion device depend tumor characteristic . No 4 light source use single treatment . The light infusion device may use single lesion multiple lesion . Following radiographic confirmation light infusion device placement , patient receive intravenous dose LS11 40 mg/m² . One hour follow completion LS11 administration , delivery 200 J/cm light energy begin . The light infusion device manually remove patient observe acute complication light infusion device removal . Precautions protection external light exposure institute begin LS11 administration maintain define throughout study period . On day 30+5 patient undergo clinical assessment tumor mass image use contrast enhance spiral CT determination volume radius tumor size , well tumor necrosis . The patient may receive 5-FU and/or leucovorin + either irinotecan oxaliplatin standard chemotherapy day 30 visit . All patient , without chemotherapy day 30 , undergo final clinical assessment final tumor image evaluation use contrast CT day 60+5 Litx treatment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Talaporfin</mesh_term>
	<criteria>Inclusion Criteria Patients metastatic liver lesion colorectal disease fail progressed chemotherapy regimen metastatic disease . Biopsy proven evidence colorectal cancer . Patients 4 few lesion great 1 cm single lesion great 7 cm maximum diameter . Age great equal 18 year . Patients must able sign inform consent . Life expectancy great equal 3 month . ECOG performance status 02 . Patients extrahepatic disease addition hepatic metastasis eligible receive systemic therapy extrahepatic disease follow Litx therapy . Off chemotherapy 4 week . Must recover chemotherapy effect . Exclusion Criteria Patients must exclude follow apply : Patients candidate complete surgical resection . Pregnancy breastfeed . A negative pregnancy test ( urine serum ) require prior enrollment . Known uncontrollable serious reaction anaphylaxis , contrast agent use study . PT PTT great 1.5X control . Platelet count less 100,000 . WBC le 2500/mm . Neutrophils le 2000/mm . Hemoglobin le 9 g/dL . Liver enzymes great 3 X ULN . Total bilirubin great 1.5 X ULN . Serum creatinine great 2.5 X ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Photodynamic therapy</keyword>
	<keyword>Liver metastasis</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Litx™</keyword>
	<keyword>Light Infusion Technology™</keyword>
	<keyword>Talaporfin sodium</keyword>
	<keyword>LS11</keyword>
	<keyword>Liver mets</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Light emittting diode ( LED )</keyword>
	<keyword>Tumor ablation</keyword>
	<keyword>Combination therapy</keyword>
</DOC>